The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation
Tóm tắt
Từ khóa
Tài liệu tham khảo
Griffiths, 2014, Taming the transplantation troll by targeting terminase, N Engl J Med, 370, 1844, 10.1056/NEJMe1401567
Stern, 2014, Cytomegalovirus serology and replication remain associated with solid organ graft rejection and graft loss in the era of prophylactic treatment, Transplantation, 98, 1013, 10.1097/TP.0000000000000160
Kotton, 2010, International consensus guidelines on the management of cytomegalovirus in solid organ transplantation, Transplantation, 89, 779, 10.1097/TP.0b013e3181cee42f
Kotton, 2013, Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation, Transplantation, 96, 333, 10.1097/TP.0b013e31829df29d
Guyatt, 2008, GRADE: an emerging consensus on rating quality of evidence and strength of recommendations, BMJ, 336, 924, 10.1136/bmj.39489.470347.AD
Jaeschke, 2008, Use of GRADE grid to reach decisions on clinical practice guidelines when consensus is elusive, BMJ, 337, a744, 10.1136/bmj.a744
Guyatt, 2008, Incorporating considerations of resources use into grading recommendations, BMJ, 336, 1170, 10.1136/bmj.39504.506319.80
Schunemann, 2008, Grading quality of evidence and strength of recommendations for diagnostic tests and strategies, BMJ, 336, 1106, 10.1136/bmj.39500.677199.AE
de Man, 1996, Patient to patient hepatitis B transmission during heart biopsy procedures. A report of the European Working Party on Viral Hepatitis in Heart Transplant Recipients, J Hosp Infect, 34, 71, 10.1016/S0195-6701(96)90127-9
Guyatt, 2008, What is “quality of evidence” and why is it important to clinicians?, BMJ, 336, 995, 10.1136/bmj.39490.551019.BE
Humar, 2006, American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation, Am J Transplant, 6, 262, 10.1111/j.1600-6143.2005.01207.x
Ljungman, 2017, Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials, Clin Infect Dis, 64, 87, 10.1093/cid/ciw668
Delforge, 2015, Evaluation of the new LIAISON(®) CMV IgG, IgM and IgG Avidity II assays, J Clin Virol, 72, 42, 10.1016/j.jcv.2015.09.002
Lagrou, 2009, Evaluation of the new architect cytomegalovirus immunoglobulin M (IgM), IgG, and IgG avidity assays, J Clin Microbiol, 47, 1695, 10.1128/JCM.02172-08
Seed, 2009, Validation of an automated immunoglobulin G-only cytomegalovirus (CMV) antibody screening assay and an assessment of the risk of transfusion transmitted CMV from seronegative blood, Transfusion, 49, 134, 10.1111/j.1537-2995.2008.01932.x
Weber, 1999, Screening of blood donors for human cytomegalovirus (HCMV) IgG antibody with an enzyme immunoassay using recombinant antigens, J Clin Virol, 14, 173, 10.1016/S1386-6532(99)00060-8
Preiksaitis, 2002, The risk of transfusion-acquired CMV infection in seronegative solid-organ transplant recipients receiving non-WBC-reduced blood components not screened for CMV antibody (1984 to 1996): experience at a single Canadian center, Transfusion, 42, 396, 10.1046/j.1525-1438.2002.00069.x
Ritter, 2013, Cytomegalovirus-specific T cells are detectable in early childhood and allow assignment of the infection status in children with passive maternal antibodies, Eur J Immunol, 43, 1099, 10.1002/eji.201243100
Schmidt, 2012, Cytomegalovirus-specific T-cell immunity to assign the infection status in individuals with passive immunity: a proof of principle, J Clin Virol, 54, 272, 10.1016/j.jcv.2012.03.001
Schmidt, 2014, Comparative analysis of assays for detection of cell-mediated immunity toward cytomegalovirus and M. tuberculosis in samples from deceased organ donors, Am J Transplant, 14, 2159, 10.1111/ajt.12787
Mayer, 2016, Dynamics of persistent oral cytomegalovirus shedding during primary infection in ugandan infants, J Infect Dis, 214, 1735, 10.1093/infdis/jiw442
Humar, 2010, Extended valganciclovir prophylaxis in D+/R− kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease: two-year results of the IMPACT study, Transplantation, 90, 1427, 10.1097/TP.0b013e3181ff1493
Humar, 2005, Clinical utility of cytomegalovirus (CMV) serology testing in high-risk CMV D+/R− transplant recipients, Am J Transplant, 5, 1065, 10.1111/j.1600-6143.2005.00797.x
Blanco-Lobo, 2016, Applying lessons learned from cytomegalovirus infection in transplant patients to vaccine design, Drug Discov Today, 21, 674, 10.1016/j.drudis.2016.03.005
Pillay, 1993, The prognostic significance of positive CMV cultures during surveillance of renal transplant recipients, Transplantation, 56, 103, 10.1097/00007890-199307000-00019
Caliendo, 2002, Distinguishing cytomegalovirus (CMV) infection and disease with CMV nucleic acid assays, J Clin Microbiol, 40, 1581, 10.1128/JCM.40.5.1581-1586.2002
Emery, 2000, Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation, Lancet, 355, 2032, 10.1016/S0140-6736(00)02350-3
Humar, 1999, Clinical utility of quantitative cytomegalovirus viral load determination for predicting cytomegalovirus disease in liver transplant recipients, Transplantation, 68, 1305, 10.1097/00007890-199911150-00015
Humar, 2002, Cytomegalovirus (CMV) virus load kinetics to predict recurrent disease in solid-organ transplant patients with CMV disease, J Infect Dis, 186, 829, 10.1086/342601
Lao, 1997, Use of polymerase chain reaction to provide prognostic information on human cytomegalovirus disease after liver transplantation, J Med Virol, 51, 152, 10.1002/(SICI)1096-9071(199703)51:3<152::AID-JMV3>3.0.CO;2-5
Razonable, 2003, Dynamics of cytomegalovirus replication during preemptive therapy with oral ganciclovir, J Infect Dis, 187, 1801, 10.1086/375194
Rollag, 2002, Cytomegalovirus DNA concentration in plasma predicts development of cytomegalovirus disease in kidney transplant recipients, Clin Microbiol Infect, 8, 431, 10.1046/j.1469-0691.2002.00449.x
Hamprecht, 1998, Discordant detection of human cytomegalovirus DNA from peripheral blood mononuclear cells, granulocytes and plasma: correlation to viremia and HCMV infection, J Clin Virol, 11, 125, 10.1016/S1386-6532(98)00046-4
Koidl, 2008, Detection of CMV DNA: is EDTA whole blood superior to EDTA plasma?, J Virol Methods, 154, 210, 10.1016/j.jviromet.2008.08.012
Lisboa, 2011, The clinical utility of whole blood versus plasma cytomegalovirus viral load assays for monitoring therapeutic response, Transplantation, 91, 231, 10.1097/TP.0b013e3181ff8719
Razonable, 2002, The clinical use of various blood compartments for cytomegalovirus (CMV) DNA quantitation in transplant recipients with CMV disease, Transplantation, 73, 968, 10.1097/00007890-200203270-00025
Tang, 2008, Cytomegalovirus DNA measurement in blood and plasma using Roche LightCycler CMV quantification reagents, Diagn Mol Pathol, 17, 166, 10.1097/PDM.0b013e3181599242
Preiksaitis, 2016, Are we there yet? Impact of the first international standard for cytomegalovirus DNA on the harmonization of results reported on plasma samples, Clin Infect Dis, 63, 583, 10.1093/cid/ciw370
Hayden, 2017, Progress in quantitative viral load testing: variability and impact of the WHO quantitative international standards, J Clin Microbiol, 55, 423, 10.1128/JCM.02044-16
Hayden, 2012, Factors contributing to variability of quantitative viral PCR results in proficiency testing samples: a multivariate analysis, J Clin Microbiol, 50, 337, 10.1128/JCM.01287-11
Jones, 2016, Commutability of cytomegalovirus WHO international standard in different matrices, J Clin Microbiol, 54, 1512, 10.1128/JCM.03292-15
Hayden, 2015, Comparative evaluation of three commercial quantitative cytomegalovirus standards by use of digital and real-time PCR, J Clin Microbiol, 53, 1500, 10.1128/JCM.03375-14
Tsai, 2016, Comparison of two commercial automated nucleic acid extraction and integrated quantitation real-time PCR platforms for the detection of cytomegalovirus in plasma, PLoS One, 11, e0160493, 10.1371/journal.pone.0160493
Hayden, 2015, Commutability of the first World Health Organization international standard for human cytomegalovirus, J Clin Microbiol, 53, 3325, 10.1128/JCM.01495-15
Hirsch, 2013, An international multicenter performance analysis of cytomegalovirus load tests, Clin Infect Dis, 56, 367, 10.1093/cid/cis900
Caliendo, 2001, Comparison of quantitative and qualitative PCR assays for cytomegalovirus DNA in plasma, J Clin Microbiol, 39, 1334, 10.1128/JCM.39.4.1334-1338.2001
Lilleri, 2009, Multicenter quality control study for human cytomegalovirus DNAemia quantification, New Microbiol, 32, 245
Abbate, 2016, Nation-wide measure of variability in HCMV, EBV and BKV DNA quantification among centers involved in monitoring transplanted patients, J Clin Virol, 82, 76, 10.1016/j.jcv.2016.07.001
Åsberg, 2007, Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients, Am J Transplant, 7, 2106, 10.1111/j.1600-6143.2007.01910.x
Dioverti, 2016, Treatment of cytomegalovirus infection and disease pre- and post-quantitative nucleic acid test standardization: does use of a more sensitive assay lead to longer treatment duration?, Clin Transplant, 30, 154, 10.1111/ctr.12671
Razonable, 2013, Virologic suppression measured by a cytomegalovirus (CMV) DNA test calibrated to the World Health Organization international standard is predictive of CMV disease resolution in transplant recipients, Clin Infect Dis, 56, 1546, 10.1093/cid/cit096
Chemaly, 2004, Correlation between viral loads of cytomegalovirus in blood and bronchoalveolar lavage specimens from lung transplant recipients determined by histology and immunohistochemistry, J Clin Microbiol, 42, 2168, 10.1128/JCM.42.5.2168-2172.2004
Solans, 1997, Bronchioloalveolar lavage in the diagnosis of CMV pneumonitis in lung transplant recipients: an immunocytochemical study, Diagn Cytopathol, 16, 350, 10.1002/(SICI)1097-0339(199704)16:4<350::AID-DC9>3.0.CO;2-H
Halme, 2008, High frequency of gastroduodenal cytomegalovirus infection in liver transplant patients, Apmis, 116, 99, 10.1111/j.1600-0463.2008.00823.x
Eid, 2010, Clinical predictors of relapse after treatment of primary gastrointestinal cytomegalovirus disease in solid organ transplant recipients, Am J Transplant, 10, 157, 10.1111/j.1600-6143.2009.02861.x
Westall, 2004, Human cytomegalovirus load in plasma and bronchoalveolar lavage fluid: a longitudinal study of lung transplant recipients, J Infect Dis, 190, 1076, 10.1086/422327
Durand, 2013, Detection of cytomegalovirus DNA in plasma as an adjunct diagnostic for gastrointestinal tract disease in kidney and liver transplant recipients, Clin Infect Dis, 57, 1550, 10.1093/cid/cit521
Fisher, 2016, Sensitivity of blood and tissue diagnostics for gastrointestinal cytomegalovirus disease in solid organ transplant recipients, Transpl Infect Dis, 18, 372, 10.1111/tid.12531
McCoy, 2014, qPCR increases sensitivity to detect cytomegalovirus in formalin-fixed, paraffin-embedded tissue of gastrointestinal biopsies, Hum Pathol, 45, 48, 10.1016/j.humpath.2013.07.040
Mills, 2013, A comparison of CMV detection in gastrointestinal mucosal biopsies using immunohistochemistry and PCR performed on formalin-fixed, paraffin-embedded tissue, Am J Surg Pathol, 37, 995, 10.1097/PAS.0b013e31827fcc33
Kerschner, 2010, Detection of human cytomegalovirus in bronchoalveolar lavage fluid of lung transplant recipients reflects local virus replication and not contamination from the throat, J Clin Microbiol, 48, 4273, 10.1128/JCM.01197-10
Buffone, 1993, The diagnosis of CMV pneumonitis in lung and heart/lung transplant patients by PCR compared with traditional laboratory criteria, Transplantation, 56, 342, 10.1097/00007890-199308000-00017
Storch, 1993, Quantitative cultures of the cell fraction and supernatant of bronchoalveolar lavage fluid for the diagnosis of cytomegalovirus pneumonitis in lung transplant recipients, J Infect Dis, 168, 1502, 10.1093/infdis/168.6.1502
Bauer, 2007, Relationship between cytomegalovirus DNA load in epithelial lining fluid and plasma of lung transplant recipients and analysis of coinfection with Epstein-Barr virus and human herpesvirus 6 in the lung compartment, J Clin Microbiol, 45, 324, 10.1128/JCM.01173-06
Gerna, 2009, Preemptive therapy for systemic and pulmonary human cytomegalovirus infection in lung transplant recipients, Am J Transplant, 9, 1142, 10.1111/j.1600-6143.2009.02616.x
Riise, 2000, Quantification of cytomegalovirus DNA in BAL fluid: a longitudinal study in lung transplant recipients, Chest, 118, 1653, 10.1378/chest.118.6.1653
Puchhammer-Stöckl, 2008, Herpesviruses and the transplanted lung: looking at the air side, J Clin Virol, 43, 415, 10.1016/j.jcv.2008.08.016
Kaminski, 2016, The cell biology of cytomegalovirus: implications for transplantation, Am J Transplant, 16, 2254, 10.1111/ajt.13791
Carbone, 2016, The immunology of posttransplant CMV infection: potential effect of CMV immunoglobulins on distinct components of the immune response to CMV, Transplantation, 100, S11, 10.1097/TP.0000000000001095
Fernandez-Ruiz, 2015, Association between individual and combined SNPs in genes related to innate immunity and incidence of CMV infection in seropositive kidney transplant recipients, Am J Transplant, 15, 1323, 10.1111/ajt.13107
de Rooij, 2011, Mannose-binding lectin and ficolin-2 gene polymorphisms predispose to cytomegalovirus (re)infection after orthotopic liver transplantation, J Hepatol, 55, 800, 10.1016/j.jhep.2011.01.039
Cervera, 2009, Influence of mannose-binding lectin gene polymorphisms on the invasiveness of cytomegalovirus disease after solid organ transplantation, Transplant Proc, 41, 2259, 10.1016/j.transproceed.2009.06.056
Kwakkel-van Erp, 2011, Mannose-binding lectin deficiency linked to cytomegalovirus (CMV) reactivation and survival in lung transplantation, Clin Exp Immunol, 165, 410, 10.1111/j.1365-2249.2011.04436.x
Sarmiento, 2017, Evaluation of humoral immunity profiles to identify heart recipients at risk for development of severe infections: a multicenter prospective study, J Heart Lung Transplant, 36, 529, 10.1016/j.healun.2016.10.004
Egli, 2014, Immunomodulatory function of interleukin 28B during primary infection with cytomegalovirus, J Infect Dis, 210, 717, 10.1093/infdis/jiu144
Lisboa, 2015, CCL8 and the immune control of cytomegalovirus in organ transplant recipients, Am J Transplant, 15, 1882, 10.1111/ajt.13207
Fernández-Ruiz, 2016, Post-transplant monitoring of NK cell counts as a simple approach to predict the occurrence of opportunistic infection in liver transplant recipients, Transpl Infect Dis, 18, 552, 10.1111/tid.12564
Sarmiento, 2012, Decreased levels of serum complement C3 and natural killer cells add to the predictive value of total immunoglobulin G for severe infection in heart transplant recipients, Transpl Infect Dis, 14, 526, 10.1111/j.1399-3062.2012.00757.x
de Rham, 2014, Expression of killer cell immunoglobulin-like receptors (KIRs) by natural killer cells during acute CMV infection after kidney transplantation, Transpl Immunol, 31, 157, 10.1016/j.trim.2014.08.002
Gonzalez, 2014, KIR-associated protection from CMV replication requires pre-existing immunity: a prospective study in solid organ transplant recipients, Genes Immun, 15, 495, 10.1038/gene.2014.39
van Duin, 2014, KIR and HLA interactions are associated with control of primary CMV infection in solid organ transplant recipients, Am J Transplant, 14, 156, 10.1111/ajt.12532
Ravens, 2017, Human γδ T cells are quickly reconstituted after stem-cell transplantation and show adaptive clonal expansion in response to viral infection, Nat Immunol, 18, 393, 10.1038/ni.3686
Knight, 2010, The role of Vδ2-negative γδ T cells during cytomegalovirus reactivation in recipients of allogeneic stem cell transplantation, Blood, 116, 2164, 10.1182/blood-2010-01-255166
Kaminski, 2016, Surveillance of γδ T cells predicts cytomegalovirus infection resolution in kidney transplants, J Am Soc Nephrol, 27, 637, 10.1681/ASN.2014100985
Crough, 2009, Immunobiology of human cytomegalovirus: from bench to bedside, Clin Microbiol Rev, 22, 76, 10.1128/CMR.00034-08
Lilleri, 2012, Antibodies against neutralization epitopes of human cytomegalovirus gH/gL/pUL128-130-131 complex and virus spreading may correlate with virus control in vivo, J Clin Immunol, 32, 1324, 10.1007/s10875-012-9739-3
Fouts, 2012, Antibodies against the gH/gL/UL128/UL130/UL131 complex comprise the majority of the anti-cytomegalovirus (anti-CMV) neutralizing antibody response in CMV hyperimmune globulin, J Virol, 86, 7444, 10.1128/JVI.00467-12
Genini, 2011, Serum antibody response to the gH/gL/pUL128-131 five-protein complex of human cytomegalovirus (HCMV) in primary and reactivated HCMV infections, J Clin Virol, 52, 113, 10.1016/j.jcv.2011.06.018
Doron, 2006, Hypogammaglobulinemia in liver transplant recipients: incidence, timing, risk factors, and outcomes, Transplantation, 81, 697, 10.1097/01.tp.0000180531.66518.9e
Ohsumi, 2014, Effect of hypogammaglobulinemia after lung transplantation: a single-institution study, Eur J Cardiothorac Surg, 45, e61, 10.1093/ejcts/ezt583
Mozer-Glassberg, 2013, Hypogammaglobulinemia in the early period after liver transplantation in children, Clin Transplant, 27, E289, 10.1111/ctr.12116
Fernandez-Ruiz, 2012, Monitoring of immunoglobulin levels identifies kidney transplant recipients at high risk of infection, Am J Transplant, 12, 2763, 10.1111/j.1600-6143.2012.04192.x
Sarmiento, 2014, Evaluation of an immunological score to assess the risk of severe infection in heart recipients, Transpl Infect Dis, 16, 802, 10.1111/tid.12284
Goldfarb, 2001, Hypogammaglobulinemia in lung transplant recipients, Transplantation, 71, 242, 10.1097/00007890-200101270-00013
Sarmiento, 2005, Hypogammaglobulinemia after heart transplantation: use of intravenous immunoglobulin replacement therapy in relapsing CMV disease, Int Immunopharmacol, 5, 97, 10.1016/j.intimp.2004.09.006
Yamani, 2005, The impact of CytoGam on cardiac transplant recipients with moderate hypogammaglobulinemia: a randomized single-center study, J Heart Lung Transplant, 24, 1766, 10.1016/j.healun.2004.11.016
Yamani, 2001, Hypogammaglobulinemia after heart transplantation: impact of pre-emptive use of immunoglobulin replacement (CytoGam) on infection and rejection outcomes, Transpl Infect Dis, 3, 40, 10.1034/j.1399-3062.2001.00008.x
Sarmiento, 2016, Early intravenous immunoglobulin replacement in hypogammaglobulinemic heart transplant recipients: results of a clinical trial, Transpl Infect Dis, 18, 832, 10.1111/tid.12610
Carbone, 2012, Restoration of humoral immunity after intravenous immunoglobulin replacement therapy in heart recipients with post-transplant antibody deficiency and severe infections, Clin Transplant, 26, E277, 10.1111/j.1399-0012.2012.01653.x
Carbone, 2007, The potential impact of substitutive therapy with intravenous immunoglobulin on the outcome of heart transplant recipients with infections, Transplant Proc, 39, 2385, 10.1016/j.transproceed.2007.06.050
Augusto, 2016, Hypogammaglobulinemia and risk of severe infection in kidney transplant recipients, Transpl Infect Dis, 18, 741, 10.1111/tid.12593
Nierenberg, 2014, Pretransplant lymphopenia is a novel prognostic factor in cytomegalovirus and noncytomegalovirus invasive infections after liver transplantation, Liver Transpl, 20, 1497
Natori, 2017, Recurrence of CMV infection and the effect of prolonged antivirals in organ transplant recipients, Transplantation, 101, 1449, 10.1097/TP.0000000000001338
Sood, 2014, Immune monitoring post liver transplant, World J Transplant, 4, 30, 10.5500/wjt.v4.i1.30
Carbone, 2012, Simultaneous monitoring of cytomegalovirus-specific antibody and T-cell levels in seropositive heart transplant recipients, J Clin Immunol, 32, 809, 10.1007/s10875-012-9670-7
Egli, 2012, State-of-the-art monitoring of cytomegalovirus-specific cell-mediated immunity after organ transplant: a primer for the clinician, Clin Infect Dis, 55, 1678, 10.1093/cid/cis818
Sester, 2016, The “ABC” of virus-specific T cell immunity in solid organ transplantation, Am J Transplant, 16, 1697, 10.1111/ajt.13684
Camargo, 2015, Potential role of CC chemokine receptor 6 in prediction of late-onset cytomegalovirus infection following solid organ transplant, Clin Transplant, 29, 492, 10.1111/ctr.12531
Walker, 2007, Ex vivo monitoring of human cytomegalovirus-specific CD8+ T-cell responses using QuantiFERON-CMV, Transpl Infect Dis, 9, 165, 10.1111/j.1399-3062.2006.00199.x
Westall, 2008, Linking CMV serostatus to episodes of CMV reactivation following lung transplantation by measuring CMV-specific CD8+ T-cell immunity, Am J Transplant, 8, 1749, 10.1111/j.1600-6143.2008.02294.x
Manuel, 2013, Assessment of cytomegalovirus-specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients: a multicenter cohort study, Clin Infect Dis, 56, 817, 10.1093/cid/cis993
Kumar, 2009, Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients, Am J Transplant, 9, 1214, 10.1111/j.1600-6143.2009.02618.x
Cantisán, 2013, Pretransplant interferon-γ secretion by CMV-specific CD8+ T cells informs the risk of CMV replication after transplantation, Am J Transplant, 13, 738, 10.1111/ajt.12049
Weseslindtner, 2012, Prospective analysis of human cytomegalovirus DNAemia and specific CD8+ T cell responses in lung transplant recipients, Am J Transplant, 12, 2172, 10.1111/j.1600-6143.2012.04076.x
Lisboa, 2012, Clinical utility of cytomegalovirus cell-mediated immunity in transplant recipients with cytomegalovirus viremia, Transplantation, 93, 195, 10.1097/TP.0b013e31823c1cd4
Bestard, 2013, Pretransplant immediately early-1-specific T cell responses provide protection for CMV infection after kidney transplantation, Am J Transplant, 13, 1793, 10.1111/ajt.12256
Mattes, 2008, Functional impairment of cytomegalovirus specific CD8 T cells predicts high-level replication after renal transplantation, Am J Transplant, 8, 990, 10.1111/j.1600-6143.2008.02191.x
Abate, 2012, Human cytomegalovirus-specific T-cell immune reconstitution in preemptively treated heart transplant recipients identifies subjects at critical risk for infection, J Clin Microbiol, 50, 1974, 10.1128/JCM.06406-11
Abate, 2010, Evaluation of cytomegalovirus (CMV)-specific T cell immune reconstitution revealed that baseline antiviral immunity, prophylaxis, or preemptive therapy but not antithymocyte globulin treatment contribute to CMV-specific T cell reconstitution in kidney transplant recipients, J Infect Dis, 202, 585, 10.1086/654931
Costa, 2011, Evaluation and significance of cytomegalovirus-specific cellular immune response in lung transplant recipients, Transplant Proc, 43, 1159, 10.1016/j.transproceed.2011.03.024
Schachtner, 2017, CMV-specific T cell monitoring offers superior risk stratification of CMV-seronegative kidney transplant recipients of a CMV-seropositive donor, Transplantation, 101, e315, 10.1097/TP.0000000000001825
Lucia, 2014, Preformed frequencies of cytomegalovirus (CMV)-specific memory T and B cells identify protected CMV-sensitized individuals among seronegative kidney transplant recipients, Clin Infect Dis, 59, 1537, 10.1093/cid/ciu589
Shabir, 2013, Impaired direct priming of CD8 T cells by donor-derived cytomegalovirus following kidney transplantation, J Am Soc Nephrol, 24, 1698, 10.1681/ASN.2013040340
Barabas, 2017, An optimized IFN-γ ELISpot assay for the sensitive and standardized monitoring of CMV protein-reactive effector cells of cell-mediated immunity, BMC Immunol, 18, 14, 10.1186/s12865-017-0195-y
Banas, 2017, Validation of T-Track® CMV to assess the functionality of cytomegalovirus-reactive cell-mediated immunity in hemodialysis patients, BMC Immunol, 18, 15, 10.1186/s12865-017-0194-z
Sester, 2001, Levels of virus-specific CD4 T cells correlate with cytomegalovirus control and predict virus-induced disease after renal transplantation, Transplantation, 71, 1287, 10.1097/00007890-200105150-00018
Gerna, 2006, Monitoring of human cytomegalovirus-specific CD4 and CD8 T-cell immunity in patients receiving solid organ transplantation, Am J Transplant, 6, 2356, 10.1111/j.1600-6143.2006.01488.x
Gerna, 2011, Virologic and immunologic monitoring of cytomegalovirus to guide preemptive therapy in solid-organ transplantation, Am J Transplant, 11, 2463, 10.1111/j.1600-6143.2011.03636.x
Sester, 2005, Differences in CMV-specific T-cell levels and long-term susceptibility to CMV infection after kidney, heart and lung transplantation, Am J Transplant, 5, 1483, 10.1111/j.1600-6143.2005.00871.x
Radha, 2005, Cellular immune responses to cytomegalovirus in renal transplant recipients, Am J Transplant, 5, 110, 10.1111/j.1600-6143.2003.00647.x
Snyder, 2016, Polyfunctional T-cell signatures to predict protection from cytomegalovirus after lung transplantation, Am J Respir Crit Care Med, 193, 78, 10.1164/rccm.201504-0733OC
Snyder, 2011, Polyfunctional cytomegalovirus-specific immunity in lung transplant recipients receiving valganciclovir prophylaxis, Am J Transplant, 11, 553, 10.1111/j.1600-6143.2010.03405.x
Egli, 2008, Cytomegalovirus-specific T-cell responses and viral replication in kidney transplant recipients, J Transl Med, 6, 29, 10.1186/1479-5876-6-29
Sester, 2008, PD-1 expression and IL-2 loss of cytomegalovirus-specific T cells correlates with viremia and reversible functional anergy, Am J Transplant, 8, 1486, 10.1111/j.1600-6143.2008.02279.x
Nebbia, 2008, Polyfunctional cytomegalovirus-specific CD4+ and pp65 CD8+ T cells protect against high-level replication after liver transplantation, Am J Transplant, 8, 2590, 10.1111/j.1600-6143.2008.02425.x
La Rosa, 2008, Programmed death-1 expression in liver transplant recipients as a prognostic indicator of cytomegalovirus disease, J Infect Dis, 197, 25, 10.1086/523652
Sund, 2010, CMV-specific T-cell immunity, viral load, and clinical outcome in seropositive renal transplant recipients: a pilot study, Clin Transplant, 24, 401, 10.1111/j.1399-0012.2009.00976.x
Kumar, 2017, An interventional study using cell-mediated immunity to personalize therapy for cytomegalovirus infection after transplantation, Am J Transplant, 17, 2468, 10.1111/ajt.14347
Brestrich, 2009, Adoptive T-cell therapy of a lung transplanted patient with severe CMV disease and resistance to antiviral therapy, Am J Transplant, 9, 1679, 10.1111/j.1600-6143.2009.02672.x
Pierucci, 2016, Novel autologous T-cell therapy for drug-resistant cytomegalovirus disease after lung transplantation, J Heart Lung Transplant, 35, 685, 10.1016/j.healun.2015.12.031
Macesic, 2015, Adoptive T cell immunotherapy for treatment of ganciclovir-resistant cytomegalovirus disease in a renal transplant recipient, Am J Transplant, 15, 827, 10.1111/ajt.13023
Gupta, 2015, Treatment of cytomegalovirus retinitis with cytomegalovirus-specific T-lymphocyte infusion, Ophthalmic Surg Lasers Imaging Retina, 46, 80, 10.3928/23258160-20150101-14
Holmes-Liew, 2015, Adoptive T-cell immunotherapy for ganciclovir-resistant CMV disease after lung transplantation, Clin Transl Immunology, 4, e35, 10.1038/cti.2015.5
Leen, 2013, Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation, Blood, 121, 5113, 10.1182/blood-2013-02-486324
Blyth, 2013, Donor-derived CMV-specific T cells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation, Blood, 121, 3745, 10.1182/blood-2012-08-448977
Lugthart, 2012, Simultaneous generation of multivirus-specific and regulatory T cells for adoptive immunotherapy, J Immunother, 35, 42, 10.1097/CJI.0b013e31823569e2
Gerdemann, 2013, Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant, Mol Ther, 21, 2113, 10.1038/mt.2013.151
Plotkin, 1991, Effect of Towne live virus vaccine on cytomegalovirus disease after renal transplant. A controlled trial, Ann Intern Med, 114, 525, 10.7326/0003-4819-114-7-525
Pass, 1999, A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant, J Infect Dis, 180, 970, 10.1086/315022
Pass, 2009, Vaccine prevention of maternal cytomegalovirus infection, N Engl J Med, 360, 1191, 10.1056/NEJMoa0804749
Griffiths, 2011, Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial, Lancet, 377, 1256, 10.1016/S0140-6736(11)60136-0
Kharfan-Dabaja, 2012, A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial, Lancet Infect Dis, 12, 290, 10.1016/S1473-3099(11)70344-9
Nakamura, 2016, Viraemia, immunogenicity, and survival outcomes of cytomegalovirus chimeric epitope vaccine supplemented with PF03512676 (CMVPepVax) in allogeneic haemopoietic stem-cell transplantation: randomised phase 1b trial, Lancet Haematol, 3, e87, 10.1016/S2352-3026(15)00246-X
Reap, 2007, Development and preclinical evaluation of an alphavirus replicon particle vaccine for cytomegalovirus, Vaccine, 25, 7441, 10.1016/j.vaccine.2007.08.016
Bernstein, 2002, Effect of previous or simultaneous immunization with canarypox expressing cytomegalovirus (CMV) glycoprotein B (gB) on response to subunit gB vaccine plus MF59 in healthy CMV-seronegative adults, J Infect Dis, 185, 686, 10.1086/339003
Berencsi, 2001, A canarypox vector-expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T cell responses in human CMV-seronegative subjects, J Infect Dis, 183, 1171, 10.1086/319680
Zhong, 2008, Induction of pluripotent protective immunity following immunisation with a chimeric vaccine against human cytomegalovirus, PLoS One, 3, e3256, 10.1371/journal.pone.0003256
Rubin, 2000, Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis, Transpl Infect Dis, 2, 112, 10.1111/j.1399-3062.2000.020303.x
Paya, 2004, Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients, Am J Transplant, 4, 611, 10.1111/j.1600-6143.2004.00382.x
Lowance, 1999, Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group, N Engl J Med, 340, 1462, 10.1056/NEJM199905133401903
Razonable, 2001, Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir, J Infect Dis, 184, 1461, 10.1086/324516
Humar, 2010, The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients, Am J Transplant, 10, 1228, 10.1111/j.1600-6143.2010.03074.x
Pang, 2009, Interlaboratory comparison of cytomegalovirus viral load assays, Am J Transplant, 9, 258, 10.1111/j.1600-6143.2008.02513.x
Couzi, 2012, High incidence of anticytomegalovirus drug resistance among D+R− kidney transplant recipients receiving preemptive therapy, Am J Transplant, 12, 202, 10.1111/j.1600-6143.2011.03766.x
Atabani, 2012, Cytomegalovirus replication kinetics in solid organ transplant recipients managed by preemptive therapy, Am J Transplant, 12, 2457, 10.1111/j.1600-6143.2012.04087.x
Sun, 2010, Preemptive therapy for cytomegalovirus based on real-time measurement of viral load in liver transplant recipients, Transpl Immunol, 23, 166, 10.1016/j.trim.2010.06.013
Khoury, 2006, Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients, Am J Transplant, 6, 2134, 10.1111/j.1600-6143.2006.01413.x
Reischig, 2008, Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation, Am J Transplant, 8, 69, 10.1111/j.1600-6143.2007.02031.x
Kliem, 2008, Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial, Am J Transplant, 8, 975, 10.1111/j.1600-6143.2007.02133.x
Witzke, 2012, Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial, Transplantation, 93, 61, 10.1097/TP.0b013e318238dab3
Asberg, 2009, Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients, Am J Transplant, 9, 1205, 10.1111/j.1600-6143.2009.02617.x
Ramanan, 2013, Cytomegalovirus infections in solid organ transplantation: a review, Infect Chemother, 45, 260, 10.3947/ic.2013.45.3.260
Reischig, 2010, Intragraft cytomegalovirus infection: a randomized trial of valacyclovir prophylaxis versus pre-emptive therapy in renal transplant recipients, Antivir Ther, 15, 23, 10.3851/IMP1485
Spinner, 2010, Impact of prophylactic versus preemptive valganciclovir on long-term renal allograft outcomes, Transplantation, 90, 412, 10.1097/TP.0b013e3181e81afc
Reischig, 2012, Long-term outcomes of pre-emptive valganciclovir compared with valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation, J Am Soc Nephrol, 23, 1588, 10.1681/ASN.2012010100
Florescu, 2014, A direct and indirect comparison meta-analysis on the efficacy of cytomegalovirus preventive strategies in solid organ transplant, Clin Infect Dis, 58, 785, 10.1093/cid/cit945
Mumtaz, 2015, Universal prophylaxis or preemptive strategy for cytomegalovirus disease after liver transplantation: a systematic review and meta-analysis, Am J Transplant, 15, 472, 10.1111/ajt.13044
Manuel, 2013, Impact of antiviral preventive strategies on the incidence and outcomes of cytomegalovirus disease in solid organ transplant recipients, Am J Transplant, 13, 2402, 10.1111/ajt.12388
Paraskeva, 2011, Cytomegalovirus replication within the lung allograft is associated with bronchiolitis obliterans syndrome, Am J Transplant, 11, 2190, 10.1111/j.1600-6143.2011.03663.x
Snyder, 2010, Cytomegalovirus pneumonitis is a risk for bronchiolitis obliterans syndrome in lung transplantation, Am J Respir Crit Care Med, 181, 1391, 10.1164/rccm.200911-1786OC
Zuk, 2010, An international survey of cytomegalovirus management practices in lung transplantation, Transplantation, 90, 672, 10.1097/TP.0b013e3181ea3955
Lisboa, 2011, Clinical utility of molecular surveillance for cytomegalovirus after antiviral prophylaxis in high-risk solid organ transplant recipients, Transplantation, 92, 1063, 10.1097/TP.0b013e31822fa4b7
Montejo, 2009, Prophylactic therapy with valgancyclovir in high-risk (cytomegalovirus D+/R−) liver transplant recipients: a single-center experience, Transplant Proc, 41, 2189, 10.1016/j.transproceed.2009.06.005
Boillat Blanco, 2011, Impact of a preemptive strategy after 3 months of valganciclovir cytomegalovirus prophylaxis in kidney transplant recipients, Transplantation, 91, 251, 10.1097/TP.0b013e318200b9f0
van der Beek, 2010, Preemptive versus sequential prophylactic-preemptive treatment regimens for cytomegalovirus in renal transplantation: comparison of treatment failure and antiviral resistance, Transplantation, 89, 320, 10.1097/TP.0b013e3181bc0301
Martin-Gandul, 2014, Viral load, CMV-specific T-cell immune response and cytomegalovirus disease in solid organ transplant recipients at higher risk for cytomegalovirus infection during preemptive therapy, Transpl Int, 27, 1060, 10.1111/tri.12378
Griffiths, 2016, Randomized controlled trials to define viral load thresholds for cytomegalovirus pre-emptive therapy, PLoS One, 11, e0163722, 10.1371/journal.pone.0163722
Boaretti, 2013, Quantification of cytomegalovirus DNA by a fully automated real-time PCR for early diagnosis and monitoring of active viral infection in solid organ transplant recipients, J Clin Virol, 56, 124, 10.1016/j.jcv.2012.10.015
Martín-Gandul, 2013, Determination, validation and standardization of a CMV DNA cut-off value in plasma for preemptive treatment of CMV infection in solid organ transplant recipients at lower risk for CMV infection, J Clin Virol, 56, 13, 10.1016/j.jcv.2012.09.017
Vinuesa, 2016, Would kinetic analyses of plasma cytomegalovirus DNA load help to reach consensus criteria for triggering the initiation of preemptive antiviral therapy in transplant recipients?, Clin Infect Dis, 63, 1533, 10.1093/cid/ciw608
Solano, 2016, Preemptive antiviral therapy for CMV infection in allogeneic stem cell transplant recipients guided by the viral doubling time in the blood, Bone Marrow Transplant, 51, 718, 10.1038/bmt.2015.303
Gimenez, 2014, Early kinetics of plasma cytomegalovirus DNA load in allogeneic stem cell transplant recipients in the era of highly sensitive real-time PCR assays: does it have any clinical value?, J Clin Microbiol, 52, 654, 10.1128/JCM.02571-13
Emery, 2002, Human cytomegalovirus (HCMV) replication dynamics in HCMV-naive and -experienced immunocompromised hosts, J Infect Dis, 185, 1723, 10.1086/340653
Schoeppler, 2013, Late-onset cytomegalovirus (CMV) in lung transplant recipients: can CMV serostatus guide the duration of prophylaxis?, Am J Transplant, 13, 376, 10.1111/j.1600-6143.2012.04339.x
Hashim, 2014, Efficacy of extended valganciclovir prophylaxis in preventing cytomegalovirus infection in pediatric kidney transplantation, Open Urol Nephrol J, 7, 152, 10.2174/1874303X01407010152
Palmer, 2010, Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: a randomized, controlled trial, Ann Intern Med, 152, 761, 10.7326/0003-4819-152-12-201006150-00003
Zamora, 2004, Following universal prophylaxis with intravenous ganciclovir and cytomegalovirus immune globulin, valganciclovir is safe and effective for prevention of CMV infection following lung transplantation, Am J Transplant, 4, 1635, 10.1111/j.1600-6143.2004.00571.x
Jaksch, 2009, Cytomegalovirus prevention in high-risk lung transplant recipients: comparison of 3- vs 12-month valganciclovir therapy, J Heart Lung Transplant, 28, 670, 10.1016/j.healun.2009.03.012
Beam, 2016, Cytomegalovirus disease is associated with higher all-cause mortality after lung transplantation despite extended antiviral prophylaxis, Clin Transplant, 30, 270, 10.1111/ctr.12686
Wiita, 2012, Cytomegalovirus disease and infection in lung transplant recipients in the setting of planned indefinite valganciclovir prophylaxis, Transpl Infect Dis, 14, 248, 10.1111/j.1399-3062.2012.00723.x
Reischig, 2005, Valacyclovir for cytomegalovirus prophylaxis reduces the risk of acute renal allograft rejection, Transplantation, 79, 317, 10.1097/01.TP.0000150024.01672.CA
Pavlopoulou, 2005, A comparative randomised study of valacyclovir vs. oral ganciclovir for cytomegalovirus prophylaxis in renal transplant recipients, Clin Microbiol Infect, 11, 736, 10.1111/j.1469-0691.2005.01215.x
Reischig, 2015, Randomized trial of valganciclovir versus valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation, Clin J Am Soc Nephrol, 10, 294, 10.2215/CJN.07020714
Reischig, 2011, Valganciclovir prophylaxis against cytomegalovirus impairs lymphocyte proliferation and activation in renal transplant recipients, Antivir Ther, 16, 1227, 10.3851/IMP1879
Kacer, 2015, Valganciclovir versus valacyclovir prophylaxis for prevention of cytomegalovirus: an economic perspective, Transpl Infect Dis, 17, 334, 10.1111/tid.12383
Lischka, 2016, Characterization of cytomegalovirus breakthrough events in a phase 2 prophylaxis trial of letermovir (AIC246, MK 8228), J Infect Dis, 213, 23, 10.1093/infdis/jiv352
Chemaly, 2014, Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation, N Engl J Med, 370, 1781, 10.1056/NEJMoa1309533
Winston, 2012, Efficacy and safety of maribavir dosed at 100 mg orally twice daily for the prevention of cytomegalovirus disease in liver transplant recipients: a randomized, double-blind, multicenter controlled trial, Am J Transplant, 12, 3021, 10.1111/j.1600-6143.2012.04231.x
Marty, 2013, CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation, N Engl J Med, 369, 1227, 10.1056/NEJMoa1303688
Heddle, 2016, AABB Committee Report: reducing transfusion-transmitted cytomegalovirus infections, Transfusion, 56, 1581, 10.1111/trf.13503
Sullivan, 2015, The role of secondary cytomegalovirus prophylaxis for kidney and liver transplant recipients, Transplantation, 99, 855, 10.1097/TP.0000000000000386
Helantera, 2011, The risk of cytomegalovirus recurrence after kidney transplantation, Transpl Int, 24, 1170, 10.1111/j.1432-2277.2011.01321.x
Nafar, 2014, Prevalence and risk factors of recurrent cytomegalovirus infection in kidney transplant recipients, Iran J Kidney Dis, 8, 231
Moreno, 2012, Epidemiology and outcome of infections in human immunodeficiency virus/hepatitis C virus-coinfected liver transplant recipients: a FIPSE/GESIDA prospective cohort study, Liver Transpl, 18, 70, 10.1002/lt.22431
Lee, 2014, Cytomegalovirus infection after acute rejection therapy in seropositive kidney transplant recipients, Transpl Infect Dis, 16, 397, 10.1111/tid.12227
Santos, 2014, Delayed-onset cytomegalovirus disease coded during hospital readmission after kidney transplantation, Transplantation, 98, 187, 10.1097/TP.0000000000000030
Ong, 2015, Cytomegalovirus seroprevalence as a risk factor for poor outcome in acute respiratory distress syndrome*, Crit Care Med, 43, 394, 10.1097/CCM.0000000000000712
Walton, 2014, Reactivation of multiple viruses in patients with sepsis, PLoS One, 9, e98819, 10.1371/journal.pone.0098819
Ong, 2016, Cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome, Intensive Care Med, 42, 333, 10.1007/s00134-015-4071-z
Limaye, 2017, Effect of ganciclovir on IL-6 levels among cytomegalovirus-seropositive adults with critical illness: a randomized clinical trial, JAMA, 318, 731, 10.1001/jama.2017.10569
Cowley, 2017, Safety and efficacy of antiviral therapy for prevention of cytomegalovirus reactivation in immunocompetent critically ill patients: a randomized clinical trial, JAMA Intern Med, 177, 774, 10.1001/jamainternmed.2017.0895
Le Page, 2013, International survey of cytomegalovirus management in solid organ transplantation after the publication of consensus guidelines, Transplantation, 95, 1455, 10.1097/TP.0b013e31828ee12e
Chamberlain, 2008, Pharmacokinetics of low and maintenance dose valganciclovir in kidney transplant recipients, Am J Transplant, 8, 1297, 10.1111/j.1600-6143.2008.02220.x
Pescovitz, 2000, Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients, Antimicrob Agents Chemother, 44, 2811, 10.1128/AAC.44.10.2811-2815.2000
Stevens, 2015, Increased risk of breakthrough infection among cytomegalovirus donor-positive/recipient-negative kidney transplant recipients receiving lower-dose valganciclovir prophylaxis, Transpl Infect Dis, 17, 163, 10.1111/tid.12349
Gabardi, 2015, Evaluation of low- versus high-dose valganciclovir for prevention of cytomegalovirus disease in high-risk renal transplant recipients, Transplantation, 99, 1499, 10.1097/TP.0000000000000570
Heldenbrand, 2016, Multicenter evaluation of efficacy and safety of low-dose versus high-dose valganciclovir for prevention of cytomegalovirus disease in donor and recipient positive (D+/R+) renal transplant recipients, Transpl Infect Dis, 18, 904, 10.1111/tid.12609
Snydman, 1987, Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients, N Engl J Med, 317, 1049, 10.1056/NEJM198710223171703
Snydman, 1993, Cytomegalovirus immune globulin prophylaxis in liver transplantation. A randomized, double-blind, placebo-controlled trial, Ann Intern Med, 119, 984, 10.7326/0003-4819-119-10-199311150-00004
Valantine, 2001, Impact of cytomegalovirus hyperimmune globulin on outcome after cardiothoracic transplantation: a comparative study of combined prophylaxis with CMV hyperimmune globulin plus ganciclovir versus ganciclovir alone, Transplantation, 72, 1647, 10.1097/00007890-200111270-00012
Florescu, 2014, An international survey of cytomegalovirus prevention and treatment practices in intestinal transplantation, Transplantation, 97, 78, 10.1097/TP.0b013e3182a6baa2
Ruttmann, 2006, Combined CMV prophylaxis improves outcome and reduces the risk for bronchiolitis obliterans syndrome (BOS) after lung transplantation, Transplantation, 81, 1415, 10.1097/01.tp.0000209439.27719.ed
Rubin, 1989, Combined antibody and ganciclovir treatment of murine cytomegalovirus-infected normal and immunosuppressed BALB/c mice, Antimicrob Agents Chemother, 33, 1975, 10.1128/AAC.33.11.1975
Miescher, 2015, In vitro evaluation of cytomegalovirus-specific hyperimmune globulins vs. standard intravenous immunoglobulins, Vox Sang, 109, 71, 10.1111/vox.12246
Germer, 2016, Functional properties of human cytomegalovirus hyperimmunoglobulin and standard immunoglobulin preparations, Ann Transplant, 21, 558, 10.12659/AOT.898050
Dole, 2016, A first-in-human study to assess the safety and pharmacokinetics of monoclonal antibodies against human cytomegalovirus in healthy volunteers, Antimicrob Agents Chemother, 60, 2881, 10.1128/AAC.02698-15
Andrassy, 2012, Is cytomegalovirus prophylaxis dispensable in patients receiving an mTOR inhibitor-based immunosuppression? A systematic review and meta-analysis, Transplantation, 94, 1208, 10.1097/TP.0b013e3182708e56
Su, 2014, Everolimus-based calcineurin-inhibitor sparing regimens for kidney transplant recipients: a systematic review and meta-analysis, Int Urol Nephrol, 46, 2035, 10.1007/s11255-014-0783-1
Radtke, 2016, Fewer cytomegalovirus complications after kidney transplantation by de novo use of mTOR inhibitors in comparison to mycophenolic acid, Transpl Infect Dis, 18, 79, 10.1111/tid.12494
Cervera, 2016, Effect of mammalian target of rapamycin inhibitors on cytomegalovirus infection in kidney transplant recipients receiving polyclonal antilymphocyte globulins: a propensity score-matching analysis, Transpl Int, 29, 1216, 10.1111/tri.12848
Sheng, 2015, The effect of sirolimus-based immunosuppression vs. conventional prophylaxis therapy on cytomegalovirus infection after liver transplantation, Clin Transplant, 29, 555, 10.1111/ctr.12552
Kobashigawa, 2013, Everolimus is associated with a reduced incidence of cytomegalovirus infection following de novo cardiac transplantation, Transpl Infect Dis, 15, 150, 10.1111/tid.12007
Díaz Molina, 2015, Effect of early conversion to everolimus together with prophylaxis with valganciclovir in the prevention of cytomegalovirus infection in heart transplant recipients, Transplant Proc, 47, 130, 10.1016/j.transproceed.2014.11.026
Durante-Mangoni, 2015, Effect of the immunosuppressive regimen on the incidence of cytomegalovirus infection in 378 heart transplant recipients: a single centre, prospective cohort study, J Clin Virol, 68, 37, 10.1016/j.jcv.2015.04.017
Ghassemieh, 2013, Decreased incidence of cytomegalovirus infection with sirolimus in a post hoc randomized, multicenter study in lung transplantation, J Heart Lung Transplant, 32, 701, 10.1016/j.healun.2013.04.010
Rittà, 2015, Everolimus-based immunosuppressive regimens in lung transplant recipients: impact on CMV infection, Antiviral Res, 113, 19, 10.1016/j.antiviral.2014.10.016
Strueber, 2016, Everolimus versus mycophenolate mofetil de novo after lung transplantation: a prospective, randomized, open-label trial, Am J Transplant, 16, 3171, 10.1111/ajt.13835
Hocker, 2016, Impact of everolimus and low-dose cyclosporin on cytomegalovirus replication and disease in pediatric renal transplantation, Am J Transplant, 16, 921, 10.1111/ajt.13649
Pascual, 2016, Role of mTOR inhibitors for the control of viral infection in solid organ transplant recipients, Transpl Infect Dis, 18, 819, 10.1111/tid.12601
Tedesco-Silva, 2015, Reduced incidence of cytomegalovirus infection in kidney transplant recipients receiving everolimus and reduced tacrolimus doses, Am J Transplant, 15, 2655, 10.1111/ajt.13327
Hibberd, 1995, Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recipients. A randomized controlled trial, Ann Intern Med, 123, 18, 10.7326/0003-4819-123-1-199507010-00002
LeFevre, 1968, Glucose transfer by red cell membrane phospholipids in H2O-CHCl-3-H2O three-layer systems, Arch Biochem Biophys, 126, 677, 10.1016/0003-9861(68)90455-4
Toyoda, 2017, Impact of desensitization on antiviral immunity in HLA-sensitized kidney transplant recipients, J Immunol Res, 2017, 5672523, 10.1155/2017/5672523
Emery, 2000, Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy, Proc Natl Acad Sci U S A, 97, 8039, 10.1073/pnas.140123497
McGavin, 2001, Ganciclovir: an update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients, Drugs, 61, 1153, 10.2165/00003495-200161080-00016
Cockcroft, 1976, Prediction of creatinine clearance from serum creatinine, Nephron, 16, 31, 10.1159/000180580
Padulles, 2016, Contribution of population pharmacokinetics to dose optimization of ganciclovir-valganciclovir in solid-organ transplant patients, Antimicrob Agents Chemother, 60, 1992, 10.1128/AAC.02130-15
Asberg, 2010, Effects of the intensity of immunosuppressive therapy on outcome of treatment for CMV disease in organ transplant recipients, Am J Transplant, 10, 1881, 10.1111/j.1600-6143.2010.03114.x
Asberg, 2016, Lessons learned from a randomized study of oral valganciclovir versus parenteral ganciclovir treatment of cytomegalovirus disease in solid organ transplant recipients: the VICTOR trial, Clin Infect Dis, 62, 1154, 10.1093/cid/ciw084
Boivin, 2009, Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir, Antivir Ther, 14, 697, 10.1177/135965350901400512
Gardiner, 2017, Role of secondary prophylaxis with valganciclovir in the prevention of recurrent cytomegalovirus disease in solid organ transplant recipients, Clin Infect Dis, 65, 2000, 10.1093/cid/cix696
Lurain, 2010, Antiviral drug resistance of human cytomegalovirus, Clin Microbiol Rev, 23, 689, 10.1128/CMR.00009-10
Fisher, 2017, Risk factors and outcomes of ganciclovir resistant cytomegalovirus infection in solid organ transplant recipients, Clin Infect Dis, 65, 57, 10.1093/cid/cix259
Hantz, 2010, Drug-resistant cytomegalovirus in transplant recipients: a French cohort study, J Antimicrob Chemother, 65, 2628, 10.1093/jac/dkq368
Myhre, 2011, Incidence and outcomes of ganciclovir-resistant cytomegalovirus infections in 1244 kidney transplant recipients, Transplantation, 92, 217, 10.1097/TP.0b013e31821fad25
Young, 2016, Ganciclovir-resistant cytomegalovirus infection in solid organ transplant recipients: a single-center retrospective cohort study, Transpl Infect Dis, 18, 390, 10.1111/tid.12537
Lurain, 2002, Analysis and characterization of antiviral drug-resistant cytomegalovirus isolates from solid organ transplant recipients, J Infect Dis, 186, 760, 10.1086/342844
Ambrose, 2016, Cytomegalovirus infection and rates of antiviral resistance following intestinal and multivisceral transplantation, Transplant Proc, 48, 492, 10.1016/j.transproceed.2015.09.070
Timpone, 2016, Resistant cytomegalovirus in intestinal and multivisceral transplant recipients, Transpl Infect Dis, 18, 202, 10.1111/tid.12507
Boivin, 2012, Incidence of cytomegalovirus UL97 and UL54 amino acid substitutions detected after 100 or 200 days of valganciclovir prophylaxis, J Clin Virol, 53, 208, 10.1016/j.jcv.2011.12.019
Jabs, 1998, Incidence of foscarnet resistance and cidofovir resistance in patients treated for cytomegalovirus retinitis. The Cytomegalovirus Retinitis and Viral Resistance Study Group, Antimicrob Agents Chemother, 42, 2240, 10.1128/AAC.42.9.2240
Schubert, 2013, Fast selection of maribavir resistant cytomegalovirus in a bone marrow transplant recipient, BMC Infect Dis, 13, 330, 10.1186/1471-2334-13-330
Strasfeld, 2010, Virologic characterization of multi-drug-resistant cytomegalovirus infection in two transplant recipients treated with maribavir, J Infect Dis, 202, 104, 10.1086/653122
Eid, 2008, Emergence of drug-resistant cytomegalovirus in the era of valganciclovir prophylaxis: therapeutic implications and outcomes, Clin Transplant, 22, 162, 10.1111/j.1399-0012.2007.00761.x
Bonatti, 2017, Use of cidofovir for cytomegalovirus disease refractory to ganciclovir in solid organ recipients, Surg Infect (Larchmt, 18, 128, 10.1089/sur.2015.266
Avery, 2016, Outcomes in transplant recipients treated with foscarnet for ganciclovir-resistant or refractory cytomegalovirus infection, Transplantation, 100, e74, 10.1097/TP.0000000000001418
Landry, 2000, A standardized plaque reduction assay for determination of drug susceptibilities of cytomegalovirus clinical isolates, Antimicrob Agents Chemother, 44, 688, 10.1128/AAC.44.3.688-692.2000
Sahoo, 2013, Detection of cytomegalovirus drug resistance mutations by next-generation sequencing, J Clin Microbiol, 51, 3700, 10.1128/JCM.01605-13
Chou, 2014, Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial, J Infect Dis, 209, 1209, 10.1093/infdis/jit654
Chou, 2014, Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing, Antimicrob Agents Chemother, 58, 4697, 10.1128/AAC.03214-14
Garrigue, 2016, Contribution of next generation sequencing to early detection of cytomegalovirus UL97 emerging mutants and viral subpopulations analysis in kidney transplant recipients, J Clin Virol, 80, 74, 10.1016/j.jcv.2016.04.017
Houldcroft, 2016, Detection of low frequency multi-drug resistance and novel putative maribavir resistance in immunocompromised pediatric patients with cytomegalovirus, Front Microbiol, 7, 1317, 10.3389/fmicb.2016.01317
Hamprecht, 2003, Ganciclovir-resistant cytomegalovirus disease after allogeneic stem cell transplantation: pitfalls of phenotypic diagnosis by in vitro selection of an UL97 mutant strain, J Infect Dis, 187, 139, 10.1086/346240
Liu, 1998, Mutations in the cytomegalovirus UL97 gene associated with ganciclovir-resistant retinitis, J Infect Dis, 177, 1176, 10.1086/515293
Campos, 2016, Human cytomegalovirus antiviral drug resistance in hematopoietic stem cell transplantation: current state of the art, Rev Med Virol, 26, 161, 10.1002/rmv.1873
Chevillotte, 2010, A new tool linking human cytomegalovirus drug resistance mutations to resistance phenotypes, Antiviral Res, 85, 318, 10.1016/j.antiviral.2009.10.004
Komatsu, 2014, Resistance of human cytomegalovirus to ganciclovir/valganciclovir: a comprehensive review of putative resistance pathways, Antiviral Res, 101, 12, 10.1016/j.antiviral.2013.10.011
Chou, 2017, Differentiated levels of ganciclovir resistance conferred by mutations at codons 591 to 603 of the cytomegalovirus UL97 kinase gene, J Clin Microbiol, 55, 2098, 10.1128/JCM.00391-17
Kleiboeker, 2014, Cytomegalovirus antiviral resistance: characterization of results from clinical specimens, Transpl Infect Dis, 16, 561, 10.1111/tid.12241
Chou, 2007, Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens, Antimicrob Agents Chemother, 51, 4160, 10.1128/AAC.00736-07
Fischer, 2016, Identification of resistance-associated HCMV UL97- and UL54-mutations and a UL97-polymporphism with impact on phenotypic drug-resistance, Antiviral Res, 131, 1, 10.1016/j.antiviral.2016.04.002
Perrottet, 2009, Valganciclovir in adult solid organ transplant recipients: pharmacokinetic and pharmacodynamic characteristics and clinical interpretation of plasma concentration measurements, Clin Pharmacokinet, 48, 399, 10.2165/00003088-200948060-00006
Gagermeier, 2014, Subtherapeutic ganciclovir (GCV) levels and GCV-resistant cytomegalovirus in lung transplant recipients, Transpl Infect Dis, 16, 941, 10.1111/tid.12317
Smith, 2010, Pharmacokinetics of acyclovir and its metabolites in cerebrospinal fluid and systemic circulation after administration of high-dose valacyclovir in subjects with normal and impaired renal function, Antimicrob Agents Chemother, 54, 1146, 10.1128/AAC.00729-09
Bedino, 2013, The role of therapeutic drug monitoring in the treatment of cytomegalovirus disease in kidney transplantation, Int Urol Nephrol, 45, 1809, 10.1007/s11255-012-0293-y
Gracia-Ahufinger, 2013, Use of high-dose ganciclovir for the treatment of cytomegalovirus replication in solid organ transplant patients with ganciclovir resistance-inducing mutations, Transplantation, 95, 1015, 10.1097/TP.0b013e31828555ac
Minces, 2014, Ganciclovir-resistant cytomegalovirus infections among lung transplant recipients are associated with poor outcomes despite treatment with foscarnet-containing regimens, Antimicrob Agents Chemother, 58, 128, 10.1128/AAC.00561-13
Patel, 2014, Resolution of mild ganciclovir-resistant cytomegalovirus disease with reduced-dose cidofovir and CMV-hyperimmune globulin, J Transplant, 2014, 342319, 10.1155/2014/342319
Kaul, 2011, First report of successful treatment of multidrug-resistant cytomegalovirus disease with the novel anti-CMV compound AIC246, Am J Transplant, 11, 1079, 10.1111/j.1600-6143.2011.03530.x
Papadopoulou, 2014, Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT, Sci Transl Med, 6, 242ra283, 10.1126/scitranslmed.3008825
Chou, 2006, Effect of cell culture conditions on the anticytomegalovirus activity of maribavir, Antimicrob Agents Chemother, 50, 2557, 10.1128/AAC.00207-06
Drouot, 2016, Artesunate demonstrates in vitro synergism with several antiviral agents against human cytomegalovirus, Antivir Ther, 21, 535, 10.3851/IMP3028
Nashan, 2012, Review of cytomegalovirus infection findings with mammalian target of rapamycin inhibitor-based immunosuppressive therapy in de novo renal transplant recipients, Transplantation, 93, 1075, 10.1097/TP.0b013e31824810e6
Ozaki, 2007, The use of sirolimus in ganciclovir-resistant cytomegalovirus infections in renal transplant recipients, Clin Transplant, 21, 675, 10.1111/j.1399-0012.2007.00699.x
Sabe, 2012, Successful outcome of ganciclovir-resistant cytomegalovirus infection in organ transplant recipients after conversion to mTOR inhibitors, Transpl Int, 25, e78, 10.1111/j.1432-2277.2012.01489.x
Avery, 2010, Utility of leflunomide in the treatment of complex cytomegalovirus syndromes, Transplantation, 90, 419, 10.1097/TP.0b013e3181e94106
Chon, 2015, Use of leflunomide in renal transplant recipients with ganciclovir-resistant/refractory cytomegalovirus infection: a case series from the University of Chicago, Case Rep Nephrol Dial, 5, 96, 10.1159/000381470
Morita, 2016, Successful low-dose leflunomide treatment for ganciclovir-resistant cytomegalovirus infection with high-level antigenemia in a kidney transplant: a case report and literature review, J Clin Virol, 82, 133, 10.1016/j.jcv.2016.07.015
Verkaik, 2013, Leflunomide as part of the treatment for multidrug-resistant cytomegalovirus disease after lung transplantation: case report and review of the literature, Transpl Infect Dis, 15, E243, 10.1111/tid.12156
Germi, 2014, Success and failure of artesunate treatment in five transplant recipients with disease caused by drug-resistant cytomegalovirus, Antiviral Res, 101, 57, 10.1016/j.antiviral.2013.10.014
Shapira, 2008, Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation, Clin Infect Dis, 46, 1455, 10.1086/587106
El-Haddad, 2016, Brincidofovir (CMX-001) for refractory and resistant CMV and HSV infections in immunocompromised cancer patients: a single-center experience, Antiviral Res, 134, 58, 10.1016/j.antiviral.2016.08.024
Chou, 2016, Novel cytomegalovirus UL54 DNA polymerase gene mutations selected in vitro that confer brincidofovir resistance, Antimicrob Agents Chemother, 60, 3845, 10.1128/AAC.00214-16
Biron, 2002, Potent and selective inhibition of human cytomegalovirus replication by 1263 W94, a benzimidazole L-riboside with a unique mode of action, Antimicrob Agents Chemother, 46, 2365, 10.1128/AAC.46.8.2365-2372.2002
Marty, 2011, Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial, Lancet Infect Dis, 11, 284, 10.1016/S1473-3099(11)70024-X
Avery, 2010, Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients, Transpl Infect Dis, 12, 489, 10.1111/j.1399-3062.2010.00550.x
Chou, 2012, Effects on maribavir susceptibility of cytomegalovirus UL97 kinase ATP binding region mutations detected after drug exposure in vitro and in vivo, Antiviral Res, 95, 88, 10.1016/j.antiviral.2012.05.013
Chou, 2013, Cytomegalovirus UL97 kinase catalytic domain mutations that confer multidrug resistance, Antimicrob Agents Chemother, 57, 3375, 10.1128/AAC.00511-13
Chou, 2015, Rapid in vitro evolution of human cytomegalovirus UL56 mutations that confer letermovir resistance, Antimicrob Agents Chemother, 59, 6588, 10.1128/AAC.01623-15
Goldner, 2014, Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure, Antimicrob Agents Chemother, 58, 610, 10.1128/AAC.01794-13
Razonable, 2013, Cytomegalovirus in solid organ transplantation, Am J Transplant, 13, 93, 10.1111/ajt.12103
Bowman, 1991, OKT3 and viral disease in pediatric liver transplant recipients, Clin Transplant, 5, 294
Iragorri, 1993, Prospective cytomegalovirus surveillance in paediatric renal transplant patients, Pediatr Nephrol, 7, 55, 10.1007/BF00861569
Green, 2006, CMV-IVIG for prevention of Epstein Barr virus disease and posttransplant lymphoproliferative disease in pediatric liver transplant recipients, Am J Transplant, 6, 1906, 10.1111/j.1600-6143.2006.01394.x
Gerna, 2008, Prophylaxis followed by preemptive therapy versus preemptive therapy for prevention of human cytomegalovirus disease in pediatric patients undergoing liver transplantation, Transplantation, 86, 163, 10.1097/TP.0b013e31817889e4
Nicastro, 2017, Effectiveness of preemptive therapy for cytomegalovirus disease in pediatric liver transplantation, Transplantation, 101, 804, 10.1097/TP.0000000000001531
Madan, 2009, A hybrid strategy for the prevention of cytomegalovirus-related complications in pediatric liver transplantation recipients, Transplantation, 87, 1318, 10.1097/TP.0b013e3181a19cda
Saitoh, 2011, A universal preemptive therapy for cytomegalovirus infections in children after live-donor liver transplantation, Transplantation, 92, 930, 10.1097/TP.0b013e31822d873d
Furuichi, 2016, Fulminant hepatic failure as a risk factor for cytomegalovirus infection in children receiving preemptive therapy after living donor liver transplantation, Transplantation, 100, 2404, 10.1097/TP.0000000000001435
Bueno, 1997, Cytomegalovirus infection after intestinal transplantation in children, Clin Infect Dis, 25, 1078, 10.1086/516113
Nayyar, 2010, Pediatric small bowel transplantation, Semin Pediatr Surg, 19, 68, 10.1053/j.sempedsurg.2009.11.009
Kranz, 2008, Acute rejection episodes in pediatric renal transplant recipients with cytomegalovirus infection, Pediatr Transplant, 12, 474, 10.1111/j.1399-3046.2007.00781.x
Smith, 2010, Subclinical viremia increases risk for chronic allograft injury in pediatric renal transplantation, J Am Soc Nephrol, 21, 1579, 10.1681/ASN.2009111188
Höcker, 2016, Cytomegalovirus infection in pediatric renal transplantation and the impact of chemoprophylaxis with (val-)ganciclovir, Transplantation, 100, 862, 10.1097/TP.0000000000000888
Lin, 2012, Assessment of cytomegalovirus hybrid preventative strategy in pediatric heart transplant patients, J Pediatric Infect Dis Soc, 1, 278, 10.1093/jpids/pis056
Mahle, 2009, Does cytomegalovirus serology impact outcome after pediatric heart transplantation?, J Heart Lung Transplant, 28, 1299, 10.1016/j.healun.2009.07.011
Danziger-Isakov, 2009, The risk, prevention, and outcome of cytomegalovirus after pediatric lung transplantation, Transplantation, 87, 1541, 10.1097/TP.0b013e3181a492e8
Paya, 1999, Indirect effects of CMV in the solid organ transplant patient, Transpl Infect Dis, 1, 8
Yamada, 2014, Long-term outcome of pediatric renal transplantation: a single center study in Japan, Pediatr Transplant, 18, 453, 10.1111/petr.12299
Danziger-Isakov, 2008, Increased mortality after pulmonary fungal infection within the first year after pediatric lung transplantation, J Heart Lung Transplant, 27, 655, 10.1016/j.healun.2008.03.010
Liu, 2009, Respiratory viral infections within one year after pediatric lung transplant, Transpl Infect Dis, 11, 304, 10.1111/j.1399-3062.2009.00397.x
Snydman, 2010, Cytomegalovirus prevention and long-term recipient and graft survival in pediatric heart transplant recipients, Transplantation, 90, 1432, 10.1097/TP.0b013e3181ffba7e
Hussain, 2007, Positive pretransplantation cytomegalovirus serology is a risk factor for cardiac allograft vasculopathy in children, Circulation, 115, 1798, 10.1161/CIRCULATIONAHA.106.627570
Indolfi, 2012, Effect of early EBV and/or CMV viremia on graft function and acute cellular rejection in pediatric liver transplantation, Clin Transplant, 26, E55, 10.1111/j.1399-0012.2011.01535.x
Camacho-Gonzalez, 2011, 24 weeks of valganciclovir prophylaxis in children after renal transplantation: a 4-year experience, Transplantation, 91, 245, 10.1097/TP.0b013e3181ffffd3
Patel, 2012, Dynamics of cell-mediated immune responses to cytomegalovirus in pediatric transplantation recipients, Pediatr Transplant, 16, 18, 10.1111/j.1399-3046.2011.01531.x
Lidehall, 2013, Cytomegalovirus-specific CD4 and CD8 T cell responses in infants and children, Scand J Immunol, 77, 135, 10.1111/sji.12013
Krampe, 2010, The value of immunoprophylaxis for cytomegalovirus infection with intravenous immunoglobulin in pediatric liver transplant recipients receiving a low-dose immunosupressive regimen, Pediatr Transplant, 14, 67, 10.1111/j.1399-3046.2008.01120.x
Florescu, 2012, Incidence, risk factors, and outcomes associated with cytomegalovirus disease in small bowel transplant recipients, Pediatr Transplant, 16, 294, 10.1111/j.1399-3046.2011.01628.x
Green, 1997, Comparison of intravenous ganciclovir followed by oral acyclovir with intravenous ganciclovir alone for prevention of cytomegalovirus and Epstein-Barr virus disease after liver transplantation in children, Clin Infect Dis, 25, 1344, 10.1086/516139
Neyts, 1995, In vivo antiherpesvirus activity of N-7-substituted acyclic nucleoside analog 2-amino-7-[(1,3-dihydroxy-2-propoxy)methyl]purine, Antimicrob Agents Chemother, 39, 56, 10.1128/AAC.39.1.56
Spivey, 2007, Safety and efficacy of prolonged cytomegalovirus prophylaxis with intravenous ganciclovir in pediatric and young adult lung transplant recipients, Pediatr Transplant, 11, 312, 10.1111/j.1399-3046.2006.00626.x
Pescovitz, 2010, Pharmacokinetics of oral valganciclovir solution and intravenous ganciclovir in pediatric renal and liver transplant recipients, Transpl Infect Dis, 12, 195, 10.1111/j.1399-3062.2009.00478.x
Vaudry, 2009, Valganciclovir dosing according to body surface area and renal function in pediatric solid organ transplant recipients, Am J Transplant, 9, 636, 10.1111/j.1600-6143.2008.02528.x
Bradley, 2016, Pharmacokinetics and safety of valganciclovir in pediatric heart transplant recipients 4 months of age and younger, Pediatr Infect Dis J, 35, 1324, 10.1097/INF.0000000000001317
Asberg, 2014, New algorithm for valganciclovir dosing in pediatric solid organ transplant recipients, Pediatr Transplant, 18, 103, 10.1111/petr.12179
Villeneuve, 2013, Valganciclovir dosing using area under the curve calculations in pediatric solid organ transplant recipients, Pediatr Transplant, 17, 80, 10.1111/petr.12030
Launay, 2012, Pharmacokinetic profile of valganciclovir in pediatric transplant recipients, Pediatr Infect Dis J, 31, 405, 10.1097/INF.0b013e3182463a19
Ranganathan, 2009, Cytomegalovirus immunoglobulin decreases the risk of cytomegalovirus infection but not disease after pediatric lung transplantation, J Heart Lung Transplant, 28, 1050, 10.1016/j.healun.2009.04.032
Renoult, 2008, Prevention of CMV disease in pediatric kidney transplant recipients: evaluation of pp67 NASBA-based pre-emptive ganciclovir therapy combined with CMV hyperimmune globulin prophylaxis in high-risk patients, Pediatr Transplant, 12, 420, 10.1111/j.1399-3046.2007.00799.x
Snydman, 2011, The impact of CMV prevention on long-term recipient and graft survival in heart transplant recipients: analysis of the Scientific Registry of Transplant Recipients (SRTR) database, Clin Transplant, 25, E455, 10.1111/j.1399-0012.2011.01459.x
Nagai, 2016, Cytomegalovirus infection after intestinal/multivisceral transplantation: a single-center experience with 210 cases, Transplantation, 100, 451, 10.1097/TP.0000000000000832
Gilbert, 2005, Human cytomegalovirus resistance to antiviral drugs, Antimicrob Agents Chemother, 49, 873, 10.1128/AAC.49.3.873-883.2005
Kim, 2012, Cytomegalovirus infection and ganciclovir resistance caused by UL97 mutations in pediatric transplant recipients, Transpl Infect Dis, 14, 611, 10.1111/j.1399-3062.2012.00760.x
Martin, 2010, Incidence and characterization of cytomegalovirus resistance mutations among pediatric solid organ transplant patients who received valganciclovir prophylaxis, J Clin Virol, 47, 321, 10.1016/j.jcv.2010.01.009